Published in Science on October 31, 2013
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature (2014) 3.73
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature (2014) 3.50
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity (2014) 2.42
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity (2014) 2.38
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature (2014) 2.33
HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (2015) 2.26
Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies. J Virol (2014) 2.09
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science (2014) 2.05
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep (2014) 2.01
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A (2014) 1.94
HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science (2015) 1.93
Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol (2015) 1.82
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol (2015) 1.70
Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity (2015) 1.66
A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. J Virol (2015) 1.66
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol (2015) 1.64
A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol (2014) 1.64
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathog (2016) 1.56
Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell (2015) 1.55
HIV gp41-mediated membrane fusion occurs at edges of cholesterol-rich lipid domains. Nat Chem Biol (2015) 1.54
Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell (2015) 1.54
Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (2014) 1.53
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell (2015) 1.46
Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One (2015) 1.46
Viral membrane fusion. Virology (2015) 1.40
Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. PLoS One (2015) 1.39
CD4-induced activation in a soluble HIV-1 Env trimer. Structure (2014) 1.38
Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science (2016) 1.36
Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell (2014) 1.28
Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell (2015) 1.27
Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer. PLoS Pathog (2015) 1.26
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity (2016) 1.26
Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties. PLoS Pathog (2015) 1.23
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell (2015) 1.20
Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep (2015) 1.18
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. Immunity (2015) 1.18
Vaccines for the 21st century. EMBO Mol Med (2014) 1.17
New approaches to HIV vaccine development. Curr Opin Immunol (2015) 1.17
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell (2015) 1.16
Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nat Commun (2015) 1.14
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science (2015) 1.14
Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol (2014) 1.12
Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. Cell Rep (2015) 1.11
Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol (2014) 1.10
Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends Biochem Sci (2015) 1.10
Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell (2016) 1.07
Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc Natl Acad Sci U S A (2015) 1.05
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. Cell Rep (2016) 1.05
Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res (2014) 1.04
Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. PLoS Pathog (2015) 1.04
Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell (2015) 1.02
Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Anal Chem (2014) 1.02
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity. J Virol (2015) 1.01
Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J Virol (2014) 1.01
Pre-fusion structure of a human coronavirus spike protein. Nature (2016) 1.01
Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol (2015) 1.00
Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology (2014) 1.00
Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J Virol (2014) 1.00
AIDS/HIV. Host controls of HIV neutralizing antibodies. Science (2014) 1.00
Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. J Virol (2015) 1.00
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science (2016) 0.99
Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. J Virol (2015) 0.99
Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc Natl Acad Sci U S A (2014) 0.99
Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins (2014) 0.99
HIV-1 vaccine immunogen design strategies. Virol J (2015) 0.98
History of vaccination. Proc Natl Acad Sci U S A (2014) 0.98
Dissociation of the trimeric gp41 ectodomain at the lipid-water interface suggests an active role in HIV-1 Env-mediated membrane fusion. Proc Natl Acad Sci U S A (2014) 0.98
HIV broadly neutralizing antibody targets. Curr Opin HIV AIDS (2015) 0.98
HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends Immunol (2016) 0.97
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol (2015) 0.97
Transplanting supersites of HIV-1 vulnerability. PLoS One (2014) 0.96
Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol (2014) 0.94
Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Virology (2015) 0.94
Progress in HIV-1 vaccine development. J Allergy Clin Immunol (2014) 0.94
Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. Structure (2015) 0.94
The Atomic Structure of the HIV-1 gp41 Transmembrane Domain and Its Connection to the Immunogenic Membrane-proximal External Region. J Biol Chem (2015) 0.94
Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc Natl Acad Sci U S A (2014) 0.94
Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies. Immunol Cell Biol (2015) 0.94
HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe (2016) 0.93
Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nat Commun (2015) 0.93
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A (2016) 0.93
Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. J Virol (2015) 0.92
Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. Nat Commun (2015) 0.92
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine (2014) 0.92
Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun (2016) 0.92
The HIV glycan shield as a target for broadly neutralizing antibodies. FEBS J (2015) 0.92
Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers. J Virol (2015) 0.91
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathog (2015) 0.91
Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope. J Virol (2014) 0.91
Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol (2015) 0.90
Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog (2014) 0.90
The external domains of the HIV-1 envelope are a mutational cold spot. Nat Commun (2015) 0.89
Epitope target structures of Fc-mediated effector function during HIV-1 acquisition. Curr Opin HIV AIDS (2014) 0.89
Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter. J Med Chem (2015) 0.89
Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. Proteins (2015) 0.89
Methods for gene transfer to the central nervous system. Adv Genet (2014) 0.88
HIV: A stamp on the envelope. Nature (2014) 0.88
Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1. Front Immunol (2014) 0.88
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr (2010) 108.52
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
Solvent content of protein crystals. J Mol Biol (1968) 106.07
XDS. Acta Crystallogr D Biol Crystallogr (2010) 67.46
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
Linking crystallographic model and data quality. Science (2012) 12.13
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2006) 7.29
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell (1988) 7.01
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science (2011) 4.30
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol (2006) 4.16
Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci U S A (2009) 3.92
STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins. Nucleic Acids Res (2004) 3.71
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A (2012) 3.30
Crystallographic model quality at a glance. Acta Crystallogr D Biol Crystallogr (2009) 3.11
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol (2001) 2.53
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat Struct Mol Biol (2012) 2.36
Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog (2010) 2.33
Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol (2001) 2.24
Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell (2010) 2.22
Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2013) 2.05
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Avoiding the pitfalls of single particle cryo-electron microscopy: Einstein from noise. Proc Natl Acad Sci U S A (2013) 1.64
Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol (2010) 1.63
Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol (2008) 1.62
Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol (2013) 1.54
Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med (2011) 1.46
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. J Virol (2010) 1.43
Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure (1999) 1.42
Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem (2012) 1.42
Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol (2013) 1.38
Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol (2004) 1.35
Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci U S A (2006) 1.29
Structure of trimeric HIV-1 envelope glycoproteins. Proc Natl Acad Sci U S A (2013) 1.29
Finding trimeric HIV-1 envelope glycoproteins in random noise. Proc Natl Acad Sci U S A (2013) 1.21
Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2011) 1.16
Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo-electron microscopy structures of the HIV-1 envelope glycoprotein complex. Proc Natl Acad Sci U S A (2013) 0.99
Structural biology. Is high-tech view of HIV too good to be true? Science (2013) 0.91
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature (2002) 9.62
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol (2002) 6.11
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med (2009) 5.87
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog (2009) 5.82
Appion: an integrated, database-driven pipeline to facilitate EM image processing. J Struct Biol (2009) 5.71
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature (2008) 5.24
Toward an AIDS vaccine. Science (2008) 4.83
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Protein production and purification. Nat Methods (2008) 3.97
AIDS vaccine models: challenging challenge viruses. Nat Med (2002) 3.92
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
HIV vaccine research: the way forward. Science (2008) 3.86
Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science (2005) 3.72
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47